{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:22:43Z","timestamp":1791411763749,"version":"4.3.3"},"reference-count":37,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide\u2019s effects on glycemic control, body weight (BW), and cardiometabolic markers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>This post hoc analysis compared baseline characteristics and changes in mean HbA1c, BW, waist circumference (WC), lipids, and blood pressure (BP) in 3,792 participants with early-onset versus later-onset T2D at week 40 (A Study of Tirzepatide [LY3298176] in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone [SURPASS-1] and A Study of Tirzepatide [LY3298176] Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes [SURPASS-2]) or week 52 (A Study of Tirzepatide [LY3298176] Versus Insulin Degludec in Participants With Type 2 Diabetes [SURPASS-3]). Analyses were performed by study on data from participants while on assigned treatment without rescue medication in case of persistent hyperglycemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>At baseline in SURPASS-2, participants with early-onset versus later-onset T2D were younger with longer diabetes duration (9 vs. 7 years, P &amp;lt; 0.001) higher glycemic levels (8.5% vs. 8.2%, P &amp;lt; 0.001), higher BW (97 vs. 93 kg, P &amp;lt; 0.001) and BMI (35 vs. 34 kg\/m2, P &amp;lt; 0.001), and a similarly abnormal lipid profile (e.g., triglycerides 167 vs. 156 mg\/dL). At week 40, similar improvements in HbA1c (\u22122.6% vs. \u22122.4%), BW (\u221214 vs. \u221213 kg), WC (\u221210 vs. \u221210 cm), triglycerides (\u221226% vs. \u221224%), HDL (7% vs. 7%), and systolic BP (\u22126 vs. \u22127 mmHg) were observed in both subgroups with tirzepatide.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Despite younger age, participants with early-onset T2D from the SURPASS program had higher glycemic levels and worse overall metabolic health at baseline versus those with later-onset T2D. In this post hoc analysis, similar improvements in HbA1c, BW, and cardiometabolic markers were observed with tirzepatide, irrespective of age at T2D diagnosis. Future studies are needed to determine long-term outcomes of tirzepatide in early-onset T2D.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc23-2356","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T15:48:51Z","timestamp":1713541731000},"page":"1056-1064","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":13,"title":["Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program"],"prefix":"10.2337","volume":"47","author":[{"given":"Philip","family":"Zeitler","sequence":"first","affiliation":[{"name":"1Children\u2019s Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo J.","family":"Galindo","sequence":"additional","affiliation":[{"name":"2University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Davies","sequence":"additional","affiliation":[{"name":"3Diabetes Research Centre, University of Leicester and the Leicester NIHR Biomedical Research Centre, Leicester General Hospital, Leicester, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon K.","family":"Bergman","sequence":"additional","affiliation":[{"name":"4Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian T.","family":"Thieu","sequence":"additional","affiliation":[{"name":"4Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Nicolay","sequence":"additional","affiliation":[{"name":"4Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Allen","sequence":"additional","affiliation":[{"name":"4Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Heine","sequence":"additional","affiliation":[{"name":"4Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-0207","authenticated-orcid":false,"given":"Clare J.","family":"Lee","sequence":"additional","affiliation":[{"name":"4Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"2024052115403700300_B1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41574-020-0334-z","article-title":"Young-onset type 2 diabetes mellitus - implications for morbidity and mortality","volume":"16","author":"Magliano","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"2024052115403700300_B2","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/S0140-6736(17)31371-5","article-title":"Type 2 diabetes in adolescents: a severe phenotype posing major clinical challenges and public health burden","volume":"389","author":"Viner","year":"2017","journal-title":"Lancet"},{"key":"2024052115403700300_B3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-8587(17)30186-9","article-title":"Type 2 diabetes in adolescents and young adults","volume":"6","author":"Lascar","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024052115403700300_B4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jama.2021.11165","article-title":"Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001-2017","volume":"326","author":"Lawrence","year":"2021","journal-title":"JAMA"},{"key":"2024052115403700300_B5","first-page":"A407","article-title":"Incidence of diabetes in United States youth by diabetes type, race\/ethnicity, and age, 2008\u20132009","volume":"63","author":"Lawrence","year":"2014","journal-title":"Diabetes"},{"key":"2024052115403700300_B6","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1001\/jama.2014.3201","article-title":"Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009","volume":"311","author":"Dabelea","year":"2014","journal-title":"JAMA"},{"key":"2024052115403700300_B7","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2337\/dc22-1702","article-title":"Incidence, severity, and presentation of type 2 diabetes in youth during the first and second year of the COVID-19 pandemic","volume":"46","author":"Sasidharan Pillai","year":"2023","journal-title":"Diabetes Care"},{"key":"2024052115403700300_B8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jpeds.2022.08.010","article-title":"The coronavirus disease 2019 pandemic is associated with a substantial rise in frequency and severity of presentation of youth-onset type 2 diabetes","volume":"251","author":"Magge","year":"2022","journal-title":"J Pediatr"},{"key":"2024052115403700300_B9","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.2337\/dci18-0052","article-title":"Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association","volume":"41","author":"Arslanian","year":"2018","journal-title":"Diabetes Care"},{"key":"2024052115403700300_B10","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1109333","article-title":"A clinical trial to maintain glycemic control in youth with type 2 diabetes","volume":"366","author":"TODAY Study Group","year":"2012","journal-title":"N Engl J Med"},{"key":"2024052115403700300_B11","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2337\/dc16-1066","article-title":"Youth-onset type 2 diabetes consensus report: current status, challenges, and priorities","volume":"39","author":"Nadeau","year":"2016","journal-title":"Diabetes Care"},{"key":"2024052115403700300_B12","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa2100165","article-title":"Long-term complications in youth-onset type 2 diabetes","volume":"385","author":"TODAY Study Group","year":"2021","journal-title":"N Engl J Med"},{"key":"2024052115403700300_B13","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2337\/dc22-2144","article-title":"Earlier age at type 2 diabetes diagnosis is associated with increased genetic risk of cardiovascular disease","volume":"46","author":"Lee","year":"2023","journal-title":"Diabetes Care"},{"key":"2024052115403700300_B14","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2337\/dc17-1144","article-title":"The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study)","volume":"42","author":"Laiteerapong","year":"2019","journal-title":"Diabetes Care"},{"key":"2024052115403700300_B15","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1161\/CIRCULATIONAHA.118.037885","article-title":"Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks","volume":"139","author":"Sattar","year":"2019","journal-title":"Circulation"},{"key":"2024052115403700300_B16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2337\/dc15-0991","article-title":"An inverse relationship between age of type 2 diabetes onset and complication risk and mortality: the impact of youth-onset type 2 diabetes","volume":"39","author":"Al-Saeed","year":"2016","journal-title":"Diabetes Care"},{"key":"2024052115403700300_B17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S2213-8587(23)00223-1","article-title":"Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation","volume":"11","author":"Emerging Risk Factors Collaboration","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024052115403700300_B18","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2337\/dc18-0787","article-title":"Impact of insulin and metformin versus metformin alone on \u03b2-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes","volume":"41","author":"RISE Consortium","year":"2018","journal-title":"Diabetes Care"},{"key":"2024052115403700300_B19","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1007\/s00125-020-05174-9","article-title":"Adults with early-onset type 2 diabetes (aged 18-39\u00a0years) are severely underrepresented in diabetes clinical research trials","volume":"63","author":"Sargeant","year":"2020","journal-title":"Diabetologia"},{"key":"2024052115403700300_B20","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S2213-8587(23)00225-5","article-title":"Current insights and emerging trends in early-onset type 2 diabetes","volume":"11","author":"Misra","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024052115403700300_B21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"2024052115403700300_B22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"2024052115403700300_B23","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"2024052115403700300_B24","first-page":"1811","author":"Del Prato","year":"2021"},{"key":"2024052115403700300_B25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: The SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"2024052115403700300_B26","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.2337\/dc23-0872","article-title":"Achieving normoglycemia with tirzepatide: analysis of SURPASS 1-4 trials","volume":"46","author":"Rosenstock","year":"2023","journal-title":"Diabetes Care"},{"key":"2024052115403700300_B27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12933-023-01797-5","article-title":"Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program","volume":"22","author":"Lingvay","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2024052115403700300_B28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2024052115403700300_B29","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: The SURPASS-6 randomized clinical trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"JAMA"},{"key":"2024052115403700300_B30","doi-asserted-by":"crossref","first-page":"108948","DOI":"10.1016\/j.diabres.2021.108948","article-title":"Differential loss of \u03b2-cell function in youth vs. adults following treatment withdrawal in the Restoring Insulin Secretion (RISE) study","volume":"178","author":"Utzschneider","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"2024052115403700300_B31","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc21-0027","article-title":"Baseline predictors of glycemic worsening in youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes in the Restoring Insulin Secretion (RISE) study","volume":"44","author":"Sam","year":"2021","journal-title":"Diabetes Care"},{"key":"2024052115403700300_B32","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.2337\/dc12-2455","article-title":"Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes","volume":"36","author":"Constantino","year":"2013","journal-title":"Diabetes Care"},{"key":"2024052115403700300_B33","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024052115403700300_B34","doi-asserted-by":"crossref","first-page":"bvad056","DOI":"10.1210\/jendso\/bvad056","article-title":"Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1)","volume":"7","author":"Lee","year":"2023","journal-title":"J Endocr Soc"},{"key":"2024052115403700300_B35","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2337\/dc23-0560","article-title":"Effect of early glycemic control in youth-onset type 2 diabetes on longer-term glycemic control and \u03b2-cell function: results from the TODAY study","volume":"46","author":"TODAY Study Group","year":"2023","journal-title":"Diabetes Care"},{"key":"2024052115403700300_B36","doi-asserted-by":"crossref","first-page":"e3384","DOI":"10.1210\/clinem\/dgac254","article-title":"Deterioration of glycemic control in youth-onset type 2 diabetes: What are the early and late predictors","volume":"107","author":"Zeitler","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2024052115403700300_B37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2337\/dc15-1206","article-title":"Pregnancy outcomes in youth with type 2 diabetes: the TODAY study experience","volume":"39","author":"Klingensmith","year":"2016","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/6\/1056\/765440\/dc232356.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/6\/1056\/765440\/dc232356.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:41:39Z","timestamp":1716306099000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/47\/6\/1056\/154513\/Early-Onset-Type-2-Diabetes-and-Tirzepatide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,4,19]]},"published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc23-2356","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]}}}